What the Xeljanz TV commercial - Museum Field Trip is about.
The Xeljanz TV Spot, 'Museum Field Trip' features a young girl and her classmates on a field trip to a museum in the city. While the other kids run around and explore, the young girl is left behind, struggling to keep up due to her arthritis pain.
As she wanders around aimlessly, she comes across a painting of a ballerina, and is struck by the grace and beauty of the dance. Moved by the image, the young girl closes her eyes and begins to imagine herself as the ballerina, gracefully twirling and spinning with ease.
Suddenly, the young girl opens her eyes and realizes that she can move without pain. She joins her classmates, laughing and running, as they explore the museum together. The Xeljanz TV Spot highlights the power of medication in helping people with arthritis manage their symptoms and enjoy a better quality of life.
Overall, the Xeljanz TV Spot, 'Museum Field Trip' is a moving portrayal of the struggles that people with arthritis face on a daily basis, and the hope and relief that medication can provide. It emphasizes the importance of finding effective treatment options and medication that can help people live their best lives, free from pain and limitations.
Xeljanz TV commercial - Museum Field Trip produced for
Xeljanz
was first shown on television on August 31, 2020.
Frequently Asked Questions about xeljanz tv spot, 'museum field trip'
Xeljanz is an oral prescription medication approved to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. It also comes in an extended-release formulation, Xeljanz XR.
Xeljanz and Xeljanz XR are made by Pfizer Inc., a pharmaceutical company located in New York, NY.
Tofacitinib is a prescription medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Ankylosing Spondylitis. Tofacitinib is available under the following different brand names: Xeljanz, Xeljanz XR.
Tofacitinib, also known as Xeljanz, is a type of drug known as a Janus kinase (JAK) inhibitor. It works by blocking the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and psoriatic arthritis.
Development timeline for Xeljanz
Date | Article |
---|
Nov 6, 2012 | Approval FDA Approves Xeljanz for Rheumatoid Arthritis |
Aug 21, 2012 | U.S. Food And Drug Administration Extends Action Date For Tofacitinib New Drug Application By Three Months |
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis.
Xeljanz contains the drug tofacitinib. It belongs to a class of drugs called Janus kinase inhibitors. These drugs help to decrease inflammation in your body. Xeljanz comes as a tablet and solution that's taken by mouth.
Over the course of 20 years Pfizer invested more than $1 billion into the discovery, development and commercialization of Xeljanz.
As the developer of XELJANZ/XELJANZ XR, Pfizer is a leader in JAK innovation.
Generic Name: tofacitinib
Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis-pcJIA).
Tofacitinib is a prescription medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Ankylosing Spondylitis. Tofacitinib is available under the following different brand names: Xeljanz, Xeljanz XR.
About XELJANZ® (tofacitinib)
XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in RA patients, and prescribed to over 300,000 adult patients (the majority of whom were RA patients) worldwide since 2012.